Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Natural products industry companies share overviews on the latest science on their dietary supplement branded ingredients and ...

For adults with type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy is associated ...

Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Noom CEO Geoff Cook discusses the company's move into longevity health, microdose GLP-1, and new diabetes program on 'Mornings with Maria.' ...

From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Use of GLP-1 receptor agonists, which have shown to be effective in diabetes and obesity treatment, is expanding into other ...

In 2025, the line between brand messaging and cultural commentary continued to blur. As the year ends, let’s look back at the ...

A local telehealth startup founded by a former wealth management executive and a health-care veteran is targeting busy ...